Insmed Incorporated (NASDAQ:INSM) COO Sells $312,159.36 in Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 4,902 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $63.68, for a total transaction of $312,159.36. Following the completion of the transaction, the chief operating officer now owns 147,539 shares of the company’s stock, valued at $9,395,283.52. This trade represents a 3.22 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total transaction of $161,181.80.

Insmed Stock Performance

Shares of NASDAQ INSM opened at $65.25 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The stock has a 50 day moving average of $71.23 and a 200-day moving average of $72.44. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $11.67 billion, a P/E ratio of -11.76 and a beta of 1.12.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analysts’ expectations of $93.36 million. Insmed’s revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.10) EPS. As a group, equities research analysts predict that Insmed Incorporated will post -5.44 EPS for the current year.

Institutional Investors Weigh In On Insmed

Several hedge funds have recently bought and sold shares of INSM. Geode Capital Management LLC increased its stake in shares of Insmed by 4.7% during the third quarter. Geode Capital Management LLC now owns 3,813,384 shares of the biopharmaceutical company’s stock worth $278,432,000 after purchasing an additional 172,664 shares during the period. Darwin Global Management Ltd. acquired a new position in Insmed in the 2nd quarter valued at $237,076,000. Principal Financial Group Inc. increased its position in Insmed by 12.9% during the 3rd quarter. Principal Financial Group Inc. now owns 1,871,890 shares of the biopharmaceutical company’s stock worth $136,648,000 after buying an additional 214,130 shares during the period. Clearbridge Investments LLC lifted its holdings in shares of Insmed by 76.8% during the second quarter. Clearbridge Investments LLC now owns 1,644,948 shares of the biopharmaceutical company’s stock worth $110,212,000 after buying an additional 714,539 shares in the last quarter. Finally, Vestal Point Capital LP boosted its position in shares of Insmed by 113.3% in the third quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company’s stock valued at $116,800,000 after acquiring an additional 850,000 shares during the period.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, November 1st. JPMorgan Chase & Co. boosted their target price on Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Truist Financial reaffirmed a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. Finally, Bank of America boosted their price objective on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, October 9th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.